Quantcast

Latest leukemia Stories

2014-10-23 08:34:28

Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility...

2014-10-21 12:32:21

WHITE PLAINS, N.Y., Oct. 21, 2014 /PRNewswire-USNewswire/ -- For the second year, The Leukemia & Lymphoma Society (LLS) will award funding to leading scientists and researchers who show promise in developing new drug therapies through the Screen to Lead Program. The collaborative program aims to support academic laboratories pursuing research directed towards medicinal chemistry and/or drug target screening in blood cancers. Members of a peer review panel select projects for...

2014-10-20 16:27:17

WHITE PLAINS, N.Y., Oct. 20, 2014 /PRNewswire-USNewswire/ -- Six academic investigators will receive grants from The Leukemia & Lymphoma Society (LLS) to support innovative ideas that that have the potential to take research in a new direction and fundamentally impact the future of blood cancer diagnosis and treatment. The second-year grant program, called The New Idea Award, looks to identify novel research strategies that involve the exploration of untested but potentially...

2014-10-20 08:31:48

Filing completed just three months after receipt of third FDA approval SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA(®) (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM), which was led by Dr. Steven Treon from the Dana-Farber Cancer...

2014-10-17 08:25:55

SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the European Commission (EC) has granted marketing approval for IMBRUVICA(®) (ibrutinib) throughout the 28 member states of the European Union (EU). IMBRUVICA, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with...

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST HANOVER, N.J., Oct. 15, 2014 /PRNewswire/ -- Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients...

2014-10-15 16:30:22

University of Pennsylvania and Children's Hospital of Philadelphia Research Team Funded by LLS for More Than 22 Years Report Today in New England Journal of Medicine that 90 Percent of Patients Achieved Complete Remission WHITE PLAINS, N.Y., Oct. 15, 2014 /PRNewswire-USNewswire/ -- Funding from The Leukemia & Lymphoma Society (LLS) over the past 22 years helped advance a study published today in the New England Journal of Medicine showing that 90 percent of children and adults...

2014-10-15 12:32:38

ST. PETERSBURG, Russia, October 15, 2014 /PRNewswire/ -- Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the government tenders. The atients' support state program allocates the highest budget for rituximab, a drug used in the treatment of hematological cancers. In 2013, 217 million dollars were appropriated from the federal budget for this drug alone. This year, for the first time, Russian biosimilar drug AcellBia will be...

2014-10-14 12:30:31

NEW BRUNSWICK, N.J., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Actinobac Biomed Inc., has received a $905,040 Small Business Technology Transfer Grant (STTR) Phase II Award from the National Institutes of Health/ National Cancer Institute to continue to develop its drug candidate, Leukothera®, as a potential treatment for B-cell lymphomas. "This NIH grant supports our assertion that Actinobac scientists are working on breakthrough research that can make a tremendous difference for...

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is for the...


Latest leukemia Reference Libraries

Clinical Leukemia
2012-05-18 15:34:28

Clinical Leukemia is a peer-reviewed medical journal published by CIG Media Group. The journal publishes articles on detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance, gene and antisense therapy; pathology, markers, and prognostic indicators, chemoprevention strategies,...

More Articles (1 articles) »
Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related